Beam Therapeutics Inc. Depreciation
Beam Therapeutics Inc. (BEAM) reported Depreciation of $5.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-04
- Beam Therapeutics Inc. depreciation for the quarter ending 2026-06-30 was $5.41M, a 2.31% decline year-over-year.
- Beam Therapeutics Inc. depreciation for the quarter ending 2026-03-31 was $5.61M, a 1.39% increase year-over-year.
- Beam Therapeutics Inc. depreciation for the quarter ending 2025-12-31 was $5.67M, a 4.13% increase year-over-year.
- Beam Therapeutics Inc. depreciation for the quarter ending 2025-09-30 was $5.56M, a 1.55% increase year-over-year.
- Beam Therapeutics Inc. depreciation for fiscal 2025 was $22.29M, a 1.68% increase from fiscal 2024.
- Beam Therapeutics Inc. depreciation for fiscal 2024 was $21.93M, a 9.56% increase from fiscal 2023.
- Beam Therapeutics Inc. depreciation for fiscal 2023 was $20.01M, a 41.96% increase from fiscal 2022.
- Beam Therapeutics Inc. depreciation for fiscal 2022 was $14.10M, a 95.76% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.41M 10-Q · filed 2026-08-04 | $11.02M 10-Q · filed 2026-08-04 | $16.68M derived: sum of 3 quarters · filed 2026-08-04 | $22.24M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $5.61M 10-Q · filed 2026-05-07 | $11.27M derived: sum of 2 quarters · filed 2026-05-07 | $16.83M derived: sum of 3 quarters · filed 2026-05-07 | $22.37M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $11.23M derived: sum of 2 quarters · filed 2026-02-24 | $16.77M derived: sum of 3 quarters · filed 2026-08-04 | $22.29M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $5.56M 10-Q · filed 2025-11-04 | $11.10M derived: sum of 2 quarters · filed 2026-08-04 | $16.63M 10-Q · filed 2025-11-04 | $22.07M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $5.54M 10-Q · filed 2026-08-04 | $11.07M 10-Q · filed 2026-08-04 | $16.51M derived: sum of 3 quarters · filed 2026-08-04 | $21.98M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $5.53M 10-Q · filed 2026-05-07 | $10.97M derived: sum of 2 quarters · filed 2026-05-07 | $16.45M derived: sum of 3 quarters · filed 2026-05-07 | $22.02M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $5.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.92M derived: sum of 2 quarters · filed 2026-02-24 | $16.49M derived: sum of 3 quarters · filed 2026-02-24 | $21.93M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $5.47M 10-Q · filed 2025-11-04 | $11.05M derived: sum of 2 quarters · filed 2025-11-04 | $16.48M 10-Q · filed 2025-11-04 | $21.84M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $5.58M 10-Q · filed 2025-08-05 | $11.01M 10-Q · filed 2025-08-05 | $16.37M derived: sum of 3 quarters · filed 2026-02-24 | $21.56M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $5.43M 10-Q · filed 2025-05-06 | $10.79M derived: sum of 2 quarters · filed 2026-02-24 | $15.98M derived: sum of 3 quarters · filed 2026-02-24 | $20.80M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.55M derived: sum of 2 quarters · filed 2026-02-24 | $15.37M derived: sum of 3 quarters · filed 2026-02-24 | $20.01M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $5.19M 10-Q · filed 2024-11-05 | $10.00M derived: sum of 2 quarters · filed 2024-11-05 | $14.65M 10-Q · filed 2024-11-05 | $18.59M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | $4.82M 10-Q · filed 2024-08-06 | $9.46M 10-Q · filed 2024-08-06 | $13.41M derived: sum of 3 quarters · filed 2025-02-25 | $16.88M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-03-31 | $4.65M 10-Q · filed 2024-05-07 | $8.59M derived: sum of 2 quarters · filed 2025-02-25 | $12.06M derived: sum of 3 quarters · filed 2025-02-25 | $15.48M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2022-12-31 | $3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $7.42M derived: sum of 2 quarters · filed 2025-02-25 | $10.84M derived: sum of 3 quarters · filed 2025-02-25 | $14.10M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $3.47M 10-Q · filed 2023-11-08 | $6.89M derived: sum of 2 quarters · filed 2023-11-08 | $10.15M 10-Q · filed 2023-11-08 | $12.71M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $3.42M 10-Q · filed 2023-08-08 | $6.68M 10-Q · filed 2023-08-08 | $9.24M derived: sum of 3 quarters · filed 2024-02-27 | $10.91M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $3.26M 10-Q · filed 2023-05-10 | $5.82M derived: sum of 2 quarters · filed 2024-02-27 | $7.50M derived: sum of 3 quarters · filed 2024-02-27 | $9.09M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $4.23M derived: sum of 2 quarters · filed 2024-02-27 | $5.83M derived: sum of 3 quarters · filed 2024-02-27 | $7.20M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $1.68M 10-Q · filed 2022-11-07 | $3.27M derived: sum of 2 quarters · filed 2022-11-07 | $4.64M 10-Q · filed 2022-11-07 | $5.94M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $1.59M 10-Q · filed 2022-08-09 | $2.97M 10-Q · filed 2022-08-09 | $4.26M derived: sum of 3 quarters · filed 2023-02-28 | $5.48M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $1.40M 10-Q · filed 2022-05-09 | $1.40M 10-Q · filed 2021-05-11 | $2.67M derived: sum of 2 quarters · filed 2023-02-28 | $3.89M derived: sum of 3 quarters · filed 2023-02-28 | $5.03M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.49M derived: sum of 2 quarters · filed 2023-02-28 | $3.63M derived: sum of 3 quarters · filed 2023-02-28 | $4.74M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $1.22M 10-Q · filed 2021-11-08 | $2.36M derived: sum of 2 quarters · filed 2021-11-08 | $3.46M 10-Q · filed 2021-11-08 | $4.46M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $1.15M 10-Q · filed 2021-08-10 | $2.25M 10-Q · filed 2021-08-10 | $3.25M derived: sum of 3 quarters · filed 2022-02-28 | $4.16M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $1.10M 10-Q · filed 2021-05-11 | $2.10M derived: sum of 2 quarters · filed 2022-02-28 | $3.01M derived: sum of 3 quarters · filed 2022-02-28 | $3.87M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.91M derived: sum of 2 quarters · filed 2022-02-28 | $2.77M derived: sum of 3 quarters · filed 2022-02-28 | $3.50M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $908.00K 10-Q · filed 2020-11-10 | $1.77M derived: sum of 2 quarters · filed 2020-11-10 | $2.50M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $858.00K 10-Q · filed 2020-08-12 | $1.59M 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | $735.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |